We are a commercial-stage biopharmaceutical company on a mission to deliver transformational medicines to patients. Headquartered in Waltham, MA with research facilities in Lawrence, KS, we develop innovative science to provide hope to people living with cancer.
Fueled by our proprietary drug discovery platform, Deciphera’s mission is to discover, develop, and deliver important new medicines to patients for the treatment of cancer. We aim to provide novel treatments for patients through inhibition of protein kinases.
We are focused on discovering, developing, and delivering important new medicines to patients for the treatment of cancer. Our commitment to patients is at the center of everything we do. We are dedicated. We are focused. We are motivated.
Our switch-control kinase inhibitor platform is based on our deep expertise in the biology of kinases. We are developing kinase inhibitors using our novel approach and building a diverse pipeline of wholly-owned drug candidates to improve patients’ quality of life.
Our employees come to work every day with a relentless drive to fight cancer and give patients hope. We have all seen the destruction cancer can cause, and that unites us in our fight. Our work extends beyond the lab and into the lives of the patients we treat.
Deciphera was founded in 2003 by Daniel L. Flynn, Ph.D. He was determined to establish an infrastructure and culture that nurtured true innovation, inspiration, and results.
He set a standard for ethics and accountability in a family company, which is still evident today in our values.
